All In Biotech

Drug Trial Radar · NCT05248672

Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers

A Phase 1 Study to Assess the Pharmacokinetics of Different Multiple Dose Regimens of CT1812 in Older Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Apr 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

Feb 15, 2022

Primary completion

Jun 1, 2022

Study completion Jun 1, 2022

Sponsor

Lead sponsor
Cognition TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This an open label study to assess the pharmacokinetics of CT1812 in normal healthy volunteers.

Conditions

  • Alzheimer Disease

Interventions

  • CT1812Drug

    Study Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK) in plasmaTime frame: Day 13 and 15.
  2. Pharmacokinetics (PK) in plasmaTime frame: Day 13 and 15.
  3. Pharmacokinetics (PK) in plasmaTime frame: Day 13 and 15.
  4. Pharmacokinetics (PK) in plasmaTime frame: Day 13 and 15.
  5. Pharmacokinetics (PK) in plasmaTime frame: Day 13 and 15.
  6. Pharmacokinetics (PK) in plasmaTime frame: Day 13 and 15.
  7. Pharmacokinetics (PK) in plasmaTime frame: Day 13 and 15.
  8. Pharmacokinetics (PK) in plasmaTime frame: Day 13 and 15.
  9. Pharmacokinetics (PK) in plasmaTime frame: Day 13 and 15.
  10. Pharmacokinetics (PK) in plasmaTime frame: Day 13 and 15.
  11. Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).Time frame: Day 13 and 15.
  12. Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).Time frame: Day 13 and 15.
  13. Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).Time frame: Day 13 and 15.
  14. Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).Time frame: Day 13 and 15.
  15. Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).Time frame: Day 13 and 15.
  16. Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).Time frame: Day 13 and 15.
  17. Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).Time frame: Day 13 and 15.
  18. Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).Time frame: Day 13 and 15.
  19. Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).Time frame: Day 13 and 15.
  20. Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).Time frame: Day 13 and 15.
  21. Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).Time frame: Day 13 and 15.
  22. Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF)- CSF/plasma ratioTime frame: Day 13 and 15.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Accel Clinical Research

    DeLand, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.